Kaplan-Meier curves for locoregional recurrence free survival (LRRFS) according to the pathologic nodal stage.

<p>Kaplan-Meier curves for locoregional recurrence free survival (LRRFS) according to the pathologic nodal stage.</p

Kaplan-Meier curves for locoregional recurrence free survival (LRRFS) according to the luminal subtype in pN1 patients.

<p>Kaplan-Meier curves for locoregional recurrence free survival (LRRFS) according to the luminal subtype in pN1 patients.</p

Kaplan-Meier curves for locoregional recurrence free survival (LRRFS) according to the number of risk factors in pN0 patients.

<p>Risk factors are age under 50 years and no use of adjuvant chemotherapy.</p

The Significance of Serum HER2 Levels at Diagnosis on Intrinsic Subtype-Specific Outcome of Operable Breast Cancer Patients

<div><p>Purpose</p><p>This study evaluated the association of serum HER2 (sHER2) levels at diagnosis with clinicopathologic parameters and disease free survival (DFS) in operable breast cancer patients according to intrinsic subtype.</p><p>Methods</p><p>The sHER2 levels were measured using a chemiluminescence immunoassay. The HER2 status in all tumor tissues was determined by immunohistochemistry, and confirmed in equivocal cases by fluorescence in situ.</p><p>Results</p><p>There were 436 consecutive stage I-III breast cancer patients with sHER2 result at diagnosis between Nov 2004 and Dec 2011. High sHER2 levels (≥ 15 ng/ml) were reported in 52 patients (11.9%) and HER2 overexpression in tumor tissue was observed in 111 patients (25.5%). High sHER2 levels were associated significantly with advanced stage (<i>P</i> < 0.001), mastectomy (<i>P</i> = 0.012), neoadjuvant chemotherapy (<i>P</i> < 0.001), anti-HER2 therapy (<i>P</i> < 0.001) and hormone therapy (<i>P</i> = 0.022). The patients with high sHER2 levels had a worse DFS (<i>P</i> < 0.001). In multivariate analysis, high sHER2 levels were associated significantly with worse DFS (HR = 2.25, 95% CI 1.27–3.99, <i>P</i> = 0.005). High sHER2 levels were associated with worse DFS in the HR+/HER2-, HR+/HER2+ and HR-/HER2+ subtypes (<i>P</i> = 0.043, 0.003 and 0.041, respectively).</p><p>Conclusions</p><p>These results show that the sHER2 level at diagnosis is a useful prognostic factor in patients with operable breast cancer, especially in the HR+/HER2-, HR+/HER2+ and HR-/HER2+ subtypes.</p></div

Relationship between serum HER2 levels and clinicopathologic characteristics.

<p>Relationship between serum HER2 levels and clinicopathologic characteristics.</p

Multivariate analysis for disease free survival.

<p>Multivariate analysis for disease free survival.</p

Disease free survival according to serum HER2 levels.

<p>sHER2 = serum HER2 levels.</p

Schematic diagrams of the location of the seven SNPs in IGF1R and strength of the pairwise-linkage disequilibrium (LD) between SNPs.

<p>Strengths of the LD between SNPs were indicated by the color scheme, measured using a combination of the statistic D’ and the LOD score.</p

IGF1R allele frequencies and genotype distribution in breast cancer controls and cases.

<p>Frequency of alleles among total genotyped subjects.</p

Intrinsic subtype specific disease free survival according to serum HER2 levels.

<p>(A) HR+/HER2- subtype; (B) HR+/HER2+ subtype; (C) HR-/HER2+ subtypes; (D) HR-/HER2- subtypes. sHER2 = serum HER2 levels; NA = not available.</p